Convalescent Plasma for Infectious Diseases: Historical Framework and Use in COVID-19
SourceClinical Microbiology Newsletter, 43, 4, (2021), pp. 23-32
Article / Letter to editor
Display more detailsDisplay less details
Clinical Microbiology Newsletter
SubjectRadboudumc 18: Healthcare improvement science RIHS: Radboud Institute for Health Sciences
Convalescent plasma has emerged as a promising therapeutic agent for patients with coronavirus disease 2019 (COVID-19), has received emergency use authorization, and is being widely used during the COVID-19 pandemic. Passive antibody therapy via plasma or serum has been successfully used to treat infectious diseases for more than a century. Passive antibody administration is based on the presumption that convalescent plasma or serum contains therapeutic antibodies that can be passively transferred to the plasma recipient. There are numerous examples in which convalescent plasma has been used successfully as post-exposure prophylaxis and treatment of infectious diseases, including previous coronavirus outbreaks. In the context of the COVID-19 pandemic, convalescent plasma was demonstrated to be safe and potentially effective among patients infected with COVID-19. This review provides an overview of the historical uses of convalescent plasma therapy, summarizes current evidence for convalescent plasma use for COVID-19, and highlights future antibody therapies.
Upload full text